Stocktoria
POSITRON CORP POSC
POSITRON CORP (POSC) earns a Piotroski F-score of 2/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $461,452 at a -2297.8% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
How it ranks in Manufacturing · percentile among 2036 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| POSC | POSITRON CORP | 2/9 | — | — | — |
| ITOC | iTonic Holdings Ltd | 1/9 | 5.57 | — | — |
| NXL | Nexalin Technology, Inc. | 4/9 | — | — | — |
| GTHP | GUIDED THERAPEUTICS INC | 3/9 | — | — | — |
| ENDV | ENDONOVO THERAPEUTICS, INC. | 3/9 | — | — | — |
| VANI | Vivani Medical, Inc. | 1/9 | -14.41 | — | — |
| HCIL | Hongchang International Co., Ltd | 2/9 | 2.23 | — | — |
About POSITRON CORP
Positron Corporation, a medical technology company, co-develops, manufactures, and sells positron emission tomography and PET-computed tomography imaging systems in the United States. The company offers Attrius PET and NeuSight PET-CT 64-slice used in non-invasive diagnosis and evaluation of coronary artery disease and supports various molecular imaging applications, including cardiology, oncology, and neurology. It also provides clinical and technical support services, such as physician interpretation training, nurse and technologist training, billing and prior-authorization assistance, physician over-read services, 24/7 clinical and technical support, priority response with after-hours service availability, equipment uptime guarantees and software upgrades, and remote system diagnostics and maintenance capabilities. The company sells its products through internal sales and marketing team. It serves healthcare providers, imaging centers, hospitals, and cardiology practices. The company was incorporated in 1983 and is headquartered in North Tonawanda, New York.
FAQ
Is POSC financially healthy?
POSITRON CORP's Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak).
Does POSC pay a dividend?
No, POSITRON CORP does not currently pay a dividend.
How profitable is POSC?
In FY2025, POSITRON CORP had a net margin of -2297.8% and a return on equity of -734.4%.
Is POSC a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on POSITRON CORP: a Piotroski F-score of 2/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.